Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema Through Pseudoexon Activation

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

HUJOVÁ Pavla SOUČEK Přemysl GRODECKÁ Lucie GROMBIŘÍKOVÁ Hana RAVČUKOVÁ Barbora KUKLÍNEK Pavel HAKL Roman LITZMAN Jiří FREIBERGER Tomáš

Year of publication 2020
Type Article in Periodical
Magazine / Source Journal of Clinical Immunology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://link.springer.com/article/10.1007/s10875-020-00753-2
Doi http://dx.doi.org/10.1007/s10875-020-00753-2
Keywords Hereditary angioedema; SERPING1; pre-mRNA splicing; pseudoexon activation; donor splice site
Description Purpose Hereditary angioedema (HAE) is a rare autosomal dominant life-threatening disease characterized by low levels of C1 inhibitor (type I HAE) or normal levels of ineffective C1 inhibitor (type II HAE), typically occurring as a consequence of a SERPING1 mutation. In some cases, a causal mutation remains undetected after using a standard molecular genetic analysis. Results Here we show a long methodological way to the final discovery of c.1029 + 384A > G, a novel deep intronic mutation in intron 6 which is responsible for HAE type I in a large family and has not been identified by a conventional diagnostic approach. This mutation results in de novo donor splice site creation and subsequent pseudoexon inclusion, the mechanism firstly described to occur in SERPING1 in this study. We additionally discovered that the proximal part of intron 6 is a region potentially prone to pseudoexon-activating mutations, since natural alternative exons and additional cryptic sites occur therein. Indeed, we confirmed the existence of at least two different alternative exons in this region not described previously. Conclusions In conclusion, our results suggest that detecting aberrant transcripts, which are often low abundant because of nonsense-mediated decay, requires a modified methodological approach. We suggest SERPING1 intron 6 sequencing and/or tailored mRNA analysis to be routinely used in HAE patients with no mutation identified in the coding sequence.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.